Biomarkers for the diagnosis of acute cellular rejection in liver transplant recipients: A review

Hepatology Research

Volumn 43, Issue 2, 2013, Pages 165-178

  Verhelst, Xavier P D ^a   Troisi, Roberto I ^a   Colle, Isabelle ^a   Geerts, Anja ^a   Van Vlierberghe, Hans ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Acute cellular rejection; Biomarkers; Genomics; Liver transplantation; Metabolomics; Proteomics

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; GLUTATHIONE TRANSFERASE ALPHA; GLUTATHIONE TRANSFERASE P1;

ACUTE GRAFT REJECTION; ANTIGEN PRESENTING CELL; APOPTOSIS; AREA UNDER THE CURVE; ASCITES; BILE; DIAGNOSTIC TEST ACCURACY STUDY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GRAFT RECIPIENT; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIVER GRAFT; LIVER TRANSPLANTATION; METABOLOMICS; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE ACTIVATION; TRANSCRIPTOMICS;

EID: 84873954619     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12012     Document Type: Review

References (87)

1. Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the Liver in Humans. Surg Gynaecol Obstet 1963; 117: 659-676.
2. Shaked A, Ghobrial RM, Merion RM etal. Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation. Am J Transplant 2009; 9 (2): 301-308.
3. Abraham SC, Furth EE. Receiver operating characteristic analysis of serum chemical parameters as tests of liver transplant rejection and correlation with histology. Transplantation 1995; 59 (5): 740-746.
4. Demetris A, Adams D, Bellamy C etal. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000; 31 (3): 792-799.
5. Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int 2008; 28 (5): 705-712.
6. Regev A, Berho M, Jeffers LJ etal. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastrenterol 2002; 97 (10): 2614-2618.
7. Sanchez-Fueyo A, Strom TB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology 2011; 140 (1): 51-64.
8. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976; 193 (4257): 1007-1008.
9. Neuhaus P, Clavien PA, Kittur D etal. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002; 8 (2): 132-142.
10. Eckhoff DE, McGuire B, Sellers M etal. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation 2000; 69 (9): 1867-1872.
11. Le Moine A, Goldman M, Abramowicz D. Multiple pathways to allograft rejection. Transplantation 2002; 73 (9): 1373-1381.
12. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Phamacol Ther 2001; 69 (3): 89-95.
13. Ratziu V. Serum fibrosis markers: death by validation or a leap of faith? J Hepatol 2010; 53 (2): 222-224.
14. Minguela A, Garcia-Alonso AM, Marin L etal. Evidence of CD28 upregulation in peripheral T cells before liver transplant acute rejection. Transpl Proc 1997; 29 (1-2): 499-500.
15. Minguela A, Miras M, Bermejo J etal. HBV and HCV infections and acute rejection differentially modulate CD95 and CD28 expression on peripheral blood lymphocytes after liver transplantation. Hum Immunol 2006; 67 (11): 884-893.
16. Boleslawski E, BenOthman S, Grabar S etal. CD25, CD28 and CD38 expression in peripheral blood lymphocytes as a tool to predict acute rejection after liver transplantation. Clin Transpl 2008; 22 (4): 494-501.
17. Hazzan M, Labalette M, Noel C, Lelievre G, Dessaint JP. Recall response to cytomegalovirus in allograft recipients: mobilization of CD57+, CD28+ cells before expansion of CD57+, CD28- cells within the CD8+ T lymphocyte compartment. Transplantation 1997; 63 (5): 693-698.
18. Perkins JD, Nelson DL, Rakela J, Grambsch PM, Krom RA. Soluble interleukin-2 receptor level as an indicator of liver allograft rejection. Transplantation 1989; 47 (1): 77-81.
19. Adams DH, Wang L, Hubscher SG, Elias E, Neuberger JM. Soluble interleukin-2 receptors in serum and bile of liver transplant recipients. Lancet 1989; 1 (8636): 469-471.
20. Platz KP, Mueller AR, Rossaint R etal. Cytokine pattern during rejection and infection after liver transplantation-improvements in postoperative monitoring? Transplantation 1996; 62 (10): 1441-1450.
21. Lalli E, Meliconi R, Conte R etal. Serum markers of immune activation and liver allograft rejection. Dig Dis Sci 1992; 37 (7): 1116-1120.
22. Ninova DI, Wiesner RH, Gores GJ, Harrison JM, Krom RA, Homburger HA. Soluble T lymphocyte markers in the diagnosis of cellular rejection and cytomegalovirus hepatitis in liver transplant recipients. J Hepatol 1994; 21 (6): 1080-1085.
23. Kita Y, Iwaki Y, Demetris AJ, Starzl TE. Evaluation of sequential serum interleukin-6 levels in liver allograft recipients. Transplantation 1994; 57 (7): 1037-1041.
24. Conti F, Frappier J, Dharancy S etal. Interleukin-15 production during liver allograft rejection in humans. Transplantation 2003; 76 (1): 210-216.
25. Imagawa DK, Millis JM, Olthoff KM etal. The role of tumor necrosis factor in allograft rejection. I. Evidence that elevated levels of tumor necrosis factor-alpha predict rejection following orthotopic liver transplantation. Transplantation 1990; 50 (2): 219-225.
26. Maury CP, Hockerstedt K, Teppo AM, Lautenschlager I, Scheinin TM. Changes in serum amyloid A protein and beta-2-microglobulin in association with liver allograft rejection. Transplantation 1984; 38 (5): 551-553.
27. Vivarelli M, Smith HM, Naoumov NV, Williams R. Quantitative assessment of serum beta-2-microglobulin in liver transplant recipients and relationship to liver graft rejection. Eur J Gastroenterol Hepatol 1995; 7 (12): 1215-1219.
28. Tilg H, Vogel W, Aulitzky WE etal. Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation. Transplantation 1990; 49 (6): 1074-1080.
29. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation 1990; 50 (4): 537-544.
30. Mueller AR, Platz KP, Haller GW etal. Adhesion molecules during adverse events after human liver transplantation. Transplant Proc 1997; 29 (7): 2822-2824.
31. Goto S, Noguchi T, Lynch SV etal. Is regular measurement of adhesion molecules and cytokines useful to predict post-liver transplant complications? Transpl Proc 1998; 30 (7): 2975-2976.
32. Lang T, Krams SM, Villanueva JC, Cox K, So S, Martinez OM. Differential patterns of circulating intercellular adhesion molecule-1 (cICAM-1) and vascular cell adhesion molecule-1 (cVCAM-1) during liver allograft rejection. Transplantation 1995; 59 (4): 584-589.
33. Ninova D, Krom RA, Wiesner RH. Hepatic allograft rejection is associated with increased levels of soluble intercellular adhesion molecule-1. Liver Transpl Surg 1995; 1 (5): 290-295.
34. Navarro VJ, Silver D, Langnas AN, Markin RS, Friedman AL, Pober JS. A pilot study of soluble adhesion molecules as surrogate markers for acute liver allograft rejection. Transplantation 1998; 65 (1): 126-130.
35. Mimuro J, Mizuta K, Kawano Y etal. Impact of acute cellular rejection on coagulation and fibrinolysis biomarkers within the immediate post-operative period in pediatric liver transplantation. Pediatr Transplant 2010; 14 (3): 369-376.
36. Ikemoto M, Tanaka T, Takai Y, Murayama H, Tanaka K, Fujita M. New ELISA system for myeloid-related protein complex (MRP8/14) and its clinical significance as a sensitive marker for inflammatory responses associated with transplant rejection. Clin Chem 2003; 49 (4): 594-600.
37. Jung DY, Park JB, Lee EN etal. Combined use of myeloid-related protein 8/14 and procalcitonin as diagnostic markers for acute allograft rejection in kidney transplantation recipients. Transpl Immunol 2008; 18 (4): 338-343.
38. Testro AG, Visvanathan K, Skinner N etal. Acute allograft rejection in human liver transplant recipients is associated with signaling through toll-like receptor 4. J Gastroenterol Hepatol 2011; 26 (1): 155-163.
39. Rivero M, Crespo J, Mayorga M, Fabrega E, Casafont F, Pons-Romero F. Involvement of the Fas system in liver allograft rejection. Am J Gastroenterol 2002; 97 (6): 1501-1506.
40. Foster PF, Sankary HN, Hart M, Ashmann M, Williams JW. Blood and graft eosinophilia as predictors of rejection in human liver transplantation. Transplantation 1989; 47 (1): 72-74.
41. Nagral A, Ben-Ari Z, Dhillon AP, Burroughs AK. Eosinophils in acute cellular rejection in liver allografts. Liver Transpl Surg 1998; 4 (5): 355-362.
42. Barnes EJ, Abdel-Rehim MM, Goulis Y etal. Applications and limitations of blood eosinophilia for the diagnosis of acute cellular rejection in liver transplantation. Am J Transplant 2003; 3 (4): 432-438.
43. Blanco-Garcia RM, Lopez-Alvarez MR, Garrido IP etal. CD28 and KIR2D receptors as sensors of the immune status in heart and liver transplantation. Hum Immunol 2011; 72 (10): 841-848.
44. Warle MC, Metselaar HJ, Hop WC etal. Early differentiation between rejection and infection in liver transplant patients by serum and biliary cytokine patterns. Transplantation 2003; 75 (1): 146-151.
45. Adams DH, Mainolfi E, Elias E, Neuberger JM, Rothlein R. Detection of circulating intercellular adhesion molecule-1 after liver transplantation-evidence of local release within the liver during graft rejection. Transplantation 1993; 55 (1): 83-87.
46. Dickson RC, Lauwers GY, Rosen CB, Cantwell R, Nelson DR, Lau JY. The utility of noninvasive serologic markers in the management of early allograft rejection in liver transplantation recipients. Transplantation 1999; 68 (2): 247-253.
47. Trull AK, Facey SP, Rees GW etal. Serum alpha-glutathione S-transferase-a sensitive marker of hepatocellular damage associated with acute liver allograft rejection. Transplantation 1994; 58 (12): 1345-1351.
48. Nagral A, Butler P, Sabin CA, Rolles K, Burroughs AK. Alpha-glutathione-S-transferase in acute rejection of liver transplant recipients. Transplantation 1998; 65 (3): 401-405.
49. Platz KP, Mueller AR, Haller GW etal. Determination of alpha- and Pi-glutathione-S-transferase will improve monitoring after liver transplantation. Transplant Proc 1997; 29 (7): 2827-2829.
50. Sameshima Y, Chia D, Terasaki PI, Imagawa DK, Busuttil RW. Appearance of the tumor marker CA 19-9 in liver transplant patients during rejection episodes. Transplantation 1992; 53 (3): 580-582.
51. Devlin J, Palmer RM, Gonde CE etal. Nitric oxide generation. A predictive parameter of acute allograft rejection. Transplantation 1994; 58 (5): 592-595.
52. Fabrega E, Casafont F, de la Pena J etal. Nitric oxide production in hepatic cell rejection of liver transplant patients. Transplant Proc 1997; 29 (1-2): 505-506.
53. Feussner G, Stech C, Dobmeyer J, Schaefer H, Otto G, Ziegler R. Serum amyloid A protein (SAA): a marker for liver allograft rejection in humans. Clin Investig 1994; 72 (12): 1007-1011.
54. Cox CJ, Valdiserri RO, Zerbe TR, Genter JL. EKTACHEM bilirubin fraction Bc as a predictor of liver transplant rejection. Transplantation 1987; 44 (4): 536-539.
55. Pan TL, Chen CL, Lin CL etal. Ceruloplasmin, a novel candidate as a diagnostic marker for liver function after liver transplantation. Transplant Proc 2000; 32 (7): 2198.
56. Umeshita K, Monden M, Tono T etal. Determination of the presence of interleukin-6 in bile after orthotopic liver transplantation. Its role in the diagnosis of acute rejection. Ann Surg 1996; 223 (2): 204-211.
57. Kim C, Aono S, Marubashi S etal. Significance of Alanine Aminopeptidase N (APN) in Bile in the Diagnosis of Acute Cellular Rejection After Liver Transplantation. J Surg Res 2012; 175 (1): 138-148.
58. Ganschow R, Baade B, Hellwege HH, Broering DC, Rogiers X, Burdelski M. Interleukin-1 receptor antagonist in ascites indicates acute graft rejection after pediatric liver transplantation. Pediatr Transplant 2000; 4 (4): 289-292.
59. Deng MC, Eisen HJ, Mehra MR etal. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006; 6 (1): 150-160.
60. Pacheco-Silva A. Immune function, as assessed by the ImmuKnow assay, correlates with clinical outcomes in transplant recipients. Nat Clin Pract Nephrol 2007; 3 (4): 196-197.
61. Kowalski RJ, Post DR, Mannon RB etal. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006; 82 (5): 663-668.
62. Dong JY, Yin H, Li RD etal. The relationship between adenosine triphosphate within CD4(+) T lymphocytes and acute rejection after liver transplantation. Clin Transpl 2011; 25 (3): E292-296.
63. Israeli M, Klein T, Sredni B etal. ImmuKnow: a new parameter in immune monitoring of pediatric liver transplantation recipients. Liver Transpl 2008; 14 (6): 893-898.
64. Hashimoto K, Miller C, Hirose K etal. Measurement of CD4+ T-cell function in predicting allograft rejection and recurrent hepatitis C after liver transplantation. Clin Transplant 2010; 24 (5): 701-708.
65. Li H, Xie HY, Zhou L etal. Copy number variation in CCL3L1 gene is associated with susceptibility to acute rejection in patients after liver transplantation. Clin Transpl 2012; 26 (2): 314-321.
66. Dhillon N, Walsh L, Kruger B etal. A single nucleotide polymorphism of Toll-like receptor 4 identifies the risk of developing graft failure after liver transplantation. J Hepatol 2010; 53 (1): 67-72.
67. Vasconcellos LM, Schachter AD, Zheng XX etal. Cytotoxic lymphocyte gene expression in peripheral blood leukocytes correlates with rejecting renal allografts. Transplantation 1998; 66 (5): 562-566.
68. Massoud O, Heimbach J, Viker K etal. Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay. Liver Transpl 2011; 17 (6): 723-732.
69. Flohe S, Speidel N, Flach R, Lange R, Erhard J, Schade FU. Expression of HSP 70 as a potential prognostic marker for acute rejection in human liver transplantation. Transpl Int 1998; 11 (2): 89-94.
70. Farid WR, Pan Q, van der Meer AJ etal. Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl 2012; 18 (3): 290-297.
71. Kobayashi S, Nagano H, Marubashi S etal. Guanylate-binding protein 2 mRNA in peripheral blood leukocytes of liver transplant recipients as a marker for acute cellular rejection. Transpl Int 2010; 23 (4): 390-396.
72. Serkova NJ, Zhang Y, Coatney JL etal. Early detection of graft failure using the blood metabolic profile of a liver recipient. Transplantation 2007; 83 (4): 517-521.
73. Fiorini RN, Nicoud IB, Fiorini JH. The use of genomics and proteomics for the recognition of transplantation rejection of solid organs. Recent patents on DNA & gene sequences 2009; 3 (1): 1-6.
74. Cheng J, Zhou L, Jiang JW etal. Proteomic analysis of differentially expressed proteins in rat liver allografts developed acute rejection. Eur Surg Res 2010; 44 (1): 43-51.
75. Nicholson JK, Lindon JC, Holmes E. "Metabonomics": understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999; 29 (11): 1181-1189.
76. Wu Y, Tao Y, Liang L etal. Metabonomic profile of rats with acute liver rejection. Omics 2009; 13 (2): 81-91.
77. Firpi RJ, Clark V, Soldevila-Pico C etal. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009; 15 (9): 1063-1071.
78. Sreekumar R, Rasmussen DL, Wiesner RH, Charlton MR. Differential allograft gene expression in acute cellular rejection and recurrence of hepatitis C after liver transplantation. Liver Transpl 2002; 8 (9): 814-821.
79. Gehrau R, Maluf D, Archer K etal. Molecular pathways differentiate hepatitis C virus (HCV) recurrence from acute cellular rejection in HCV liver recipients. Mol Med 2011; 17 (7-8): 824-833.
80. Takemoto SK, Zeevi A, Feng S etal. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4 (7): 1033-1041.
81. Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 2008; 86 (3): 377-383.
82. Kfoury AG, Renlund DG, Snow GL etal. A clinical correlation study of severity of antibody-mediated rejection and cardiovascular mortality in heart transplantation. J Heart Lung Transplant 2009; 28 (1): 51-57.
83. Taner T, Gandhi MJ, Sanderson SO etal. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12 (6): 1504-1510.
84. Chan KM, Lee CS, Wu TJ, Lee CF, Chen TC, Lee WC. Clinical perspective of acute humoral rejection after blood type-compatible liver transplantation. Transplantation 2011; 91 (5): e29-30.
85. Kamar N, Lavayssiere L, Muscari F etal. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. World J Gastroenterol 2009; 15 (27): 3426-3430.
86. Wilson CH, Agarwal K, Carter V etal. Late humoral rejection in a compliant ABO-compatible liver transplant recipient. Transplantation 2006; 82 (7): 988-989.
87. Paterno F, Shiller M, Tillery G etal. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012; 12 (9): 2526-2531.